This protocol is judged by an institutional overview board, an unbiased team that reviews any clinical trials involving human beings. If a review will involve a Routine I drug, after the board approves the protocol as moral, the scientists need to apply for an investigational new drug (IND) range within the FDA.When under the affect of the drug, t